Literature DB >> 984764

Comparative activity in vitro of ticarcillin, BL-P1654, and carbenicillin.

T C Eickhoff, J M Ehret.   

Abstract

The activity of ticarcillin, BL-P1654, and carbenicillin was compared in vitro using a microtiter tube dilution test in Mueller-Hinton broth against 50 recent clinical isolates each of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella species, Enterobacter species, Proteus species, and Pseudomonas aeruginosa. Bactericidal end points were determined using a modified Steers replicator. Ticarcillin was generally two to four times more active against all organisms tested except S. epidermidis against which BL-P1654 was most active. Median minimum inhibitory concentrations in micrograms per milliliter were for S. aureus: ticarcillin (6.2), carbenicillin (12.5), BL-P1654 (25); for S. epidermidis: BL-P1654 (1.6), ticarcillin (3.2), carbenicillin (3.2); for E. coli: ticarcillin (3.2), BL-P1654 (6.2), carbenicillin (6.2); for Klebsiella sp.: >100 for all three drugs; for Enterobacter sp.: ticarcillin (3.2), carbenicillin (6.2), BL-P1654 (12.5); for Proteus sp.: ticarcillin (1.6), carbenicillin (1.6), BL-P1654 (3.2); for P. aeruginosa: ticarcillin (31), BL-P1654 (62), carbenicillin (125). Bactericidal end points were dependent on both the drug and the species but were in general no more than twofold more than the minimum inhibitory concentration with the exception of BL-P1654 against P. aeruginosa. BL-P1654 was bactericidal for only 60% of the strains tested at a concentration of 500 mug/ml.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984764      PMCID: PMC429728          DOI: 10.1128/AAC.10.2.241

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative in vitro evaluation of BL-P1654 and carbenicillin against Pseudomonas.

Authors:  G D Overturf; R Ressler; J Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Ticarcillin, a new semisynthetic penicillin active on Pseudomonas aeruginosa: in vitro activity and blood levels in man.

Authors:  J Klastersky; A Henri; D Daneau
Journal:  J Clin Pharmacol       Date:  1974-04       Impact factor: 3.126

3.  Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic.

Authors:  R Wise; D S Reeves
Journal:  Chemotherapy       Date:  1974       Impact factor: 2.544

4.  Preliminary clinical experience with ticarcillin (BRL 2288) in 101 patients treated for severe respiratory infections.

Authors:  A Pines; G Khaja; H Raafat; K S Sreedharan
Journal:  Chemotherapy       Date:  1974       Impact factor: 2.544

5.  Ticarcillin vs carbenicillin: clinical pharmacokinetics.

Authors:  R D Libke; J T Clarke; E D Ralph; R P Luthy; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

6.  BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  E R Wald; H C Standiford; B A Tatem; F M Calia; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

7.  In vitro studies of a new semisynthetic penicillin, 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid.

Authors:  G P Bodey; D Stewart
Journal:  Appl Microbiol       Date:  1969-07

8.  In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin.

Authors:  G P Bodey; B Deerhake
Journal:  Appl Microbiol       Date:  1971-01

9.  Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288).

Authors:  V Rodriguez; J Inagaki; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1973-07       Impact factor: 5.191

10.  Ticarcillin therapy of infections.

Authors:  V Rodriguez; G P Bodey; N Horikoshi; J Inagaki; K B McCredie
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

View more
  3 in total

1.  Susceptibility and tolerance of beta-lactamase-producing, methicillin-sensitive strains of Staphylococcus aureus towards seven broad-spectrum penicillins.

Authors:  R Wehrli; A von Graevenitz; R Lüthy
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

2.  [Current chemotherapy of infections caused by Pseudomonas aeruginosa (author's transl)].

Authors:  A Bauernfeind; C Petermüller; M Dietzel
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 3.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.